Fenofibrate Versus Curcumin in Type 2 Diabetic Patients

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effect of fenofibrate versus curcumin on glycemic status, lipids profile, hs-CRP, sirtuin-1 and fetuin-A in type 2 diabetic patients who are taking glimepiride.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rehab Werida
• Treatments: Curcumin; Fenofibrate; Glimepiride

Criteria

Inclusion Criteria:

• 60 Patients with type 2 DM diagnosed clinically.

• The age ranged from 35 to 70 years.

• There are no limits to the duration of DM and gender.

• HbA1c ≥ 7

Exclusion Criteria:

1. Other types of DM

2. Hypersensitivity to the drug

3. Abnormal liver function

4. Patients with renal impairment (eGFR ≤ 60 ml/min)

5. Addition of any antidiabetic medications or insulin during follows up.

6. Pregnancy, lactation or child-bearing potential. 7. No insulin therapy and no use of antioxidants, multivitamin.